Gail Roboz, MD, from the Weill Medical College of Cornell University, New York City, NY, explores exciting next-generation agents for the treatment of acute myeloid leukemia (AML), such as guadecitabine, a next-generation DNA hypomethylating agent that has the potential to be more effective than decitabine. A similar concept has previously been used for the development of the CPX-351, a liposomal formulation of cytarabine and daunorubicin, which received FDA approval for the treatment of high-risk AML. This video was recorded at the 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias, held in Budapest, Hungary.
Combining existing drugs for the creation of novel AML therapies
